Structure of Alpelisib-Piqray

Alpelisib (Alpelisib)-Piqray is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent anti-tumor activity. It acts by selectively inhibiting class I PI3K p110α2, a lipid kinase that functions in a variety of biological processes, including proliferation, survival, differentiation, and metabolism. Apelix is u200bu200bdesigned to target this enzyme, which is mutated in nearly 30% of human cancers, leading to overactivation.

Apelix is a kinase inhibitor with the chemical name (2S)-N1-[4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide. Alpelisib is a white to almost white powder, and film-coated tablets are available for oral administration in three strengths containing 50 mg, 150 mg and 200 mg of Alpelisib. The tablets also contain hypromellose, magnesium stearate, mannitol, microcrystalline cellulose and sodium starch glycolate.

The original drug of Apellis is not marketed in the country and therefore cannot be included in medical insurance. There are European and Indian versions of the original Apelvis drug sold overseas. The ingredients are basically the same. The price of the European version of 150mg*56 tablets per box may be more than 4 RMB 40,000 ( (The price may fluctuate due to the exchange rate), The price of the Indian version150mg*28 tablets per box may be more than 5,000 yuan (the price may fluctuate due to the exchange rate). There are currently no generic versions of Apelvis produced and marketed.